Biologics·Jul 30, 2026
Autologous cell therapy is a procedure, not a product. The outcome depends on harvest technique, processing consistency, delivery, and post-procedure environment. These are the operational protocols we recommend for the most common evidence-supported indications.
Universal harvest and processing standards
- Harvest under fluoroscopy or landmark technique; iliac crest for BMAC, lower abdomen/flanks for adipose.
- Anticoagulant: heparinized syringe for BMAC to prevent clotting during processing.
- Concentration: 4–8× starting volume for BMAC; count nucleated cells and MSC surrogate markers per lot.
- Use closed system processing when available; sterility is the single most important risk control.
Orthopedic protocols
Knee osteoarthritis
- BMAC: 40–60 mL iliac crest aspirate concentrated to 4–8 mL.
- Intra-articular injection under ultrasound guidance; distribute across medial and lateral compartments.
- Single injection; consider PRP maintenance at 6 months.
- Non–weight-bearing crutches for 48 h; graded return over 4 weeks.
Rotator cuff surgery augmentation
- BMAC delivery at the tendon footprint at time of arthroscopic repair.
- Improves healing rates in retear-prone constructs.
Non-union fracture
- BMAC combined with structural allograft or autograft in operative revision.
- Compression through fixation; standard immobilization.
Osteonecrosis of the femoral head (early stage)
- Core decompression combined with BMAC injection into the necrotic zone.
- Post-op non–weight-bearing per surgical protocol.
Aesthetic / reconstructive protocols (mechanically processed adipose)
Soft tissue volume augmentation
- Lipoaspirate harvested via low-vacuum, standard cannula.
- Mechanical processing to concentrated adipose graft.
- Deposition in micro-aliquots along multiple planes for graft survival.
Adipose scaffolding around chronic wounds
- Peri-wound adipose grafting to improve local perfusion and matrix support.
- Adjunct to standard wound care, not a replacement.
Wound care protocols
- BMAC applied topically to debrided wound bed for select chronic wounds.
- Combine with amniotic membrane coverage for scaffolding.
- Weekly assessment and re-application as indicated.
Device sequencing that improves outcome
- Pre-injection ECSWT: mechanotransductive priming of the target tissue 48–72 hours before BMAC injection.
- Post-injection HPLT: supports mitochondrial ATP output during the proliferative phase; weekly for 4 weeks.
- Bracing / offloading: reduces mechanical noise on the treated tissue during the first 2–4 weeks.
Head-to-head with alternatives
- vs PRP: BMAC delivers cells + growth factors; PRP delivers growth factors alone. BMAC is preferred for more advanced degeneration, PRP for cost and simplicity in earlier disease.
- vs amniotic: autologous eliminates allogeneic concerns and provides living cells; amniotic offers ECM scaffolding without living cells and is often more convenient.
- vs exosomes: exosomes offer cell-free signaling with lower regulatory complexity; autologous adds a cellular component but at greater procedural burden.
Regulatory and consent considerations
- Frame the procedure as same-day autologous minimally manipulated homologous use.
- Document harvest, processing, and delivery details for every patient.
- Do not market cell numbers, MSC potency, or systemic effects beyond documented indication.
- Have a written informed consent that reflects the current FDA framing.
Common protocol failures
- Under-yield harvest — small-volume BMAC without concentration verification.
- Skipping ultrasound guidance for intra-articular delivery.
- Aggressive return-to-load in the first 2 weeks.
- Marketing systemic anti-aging effects that exceed the evidence base.